MS Newswire
Obamacare Will Be CATASTROPHIC (4/2010) - Basil & Spice
Posted Tue, 04/13/2010 - 07:35
Basil & Spice Dr. English is the Clinical Research Director at the Multiple Sclerosis Center of Atlanta, a non-profit organization for the treatment of patients with ... and more » |
Multiple Sclerosis fundraiser walk slated - Bend Bulletin
Posted Tue, 04/13/2010 - 07:11
 PennLive.com | Bend Bulletin National Multiple Sclerosis Society's Oregon chapter is hosting a 5K walk fundraiser to raise awareness and money for multiple sclerosis programs. ... Volunteers help Multiple Sclerosis Society clients with household projectsPennLive.com Annual Walk for Multiple Sclerosis in Toledo13abc.com Ocean City MS Walk - WorcesterWMDT TriCities.com -NJ TODAY -Caledon Enterprise all 21 news articles » |
Acorda Therapeutics Announces Data on AMPYRA(TM) (dalfampridine) Presented at ... - MarketWatch (press release)
Posted Tue, 04/13/2010 - 07:06
MarketWatch (press release) AMPYRA is a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an ... Acorda Therapeutics Announces Data on AMPYRA(TM) (dalfampridine) Presented at ...istockAnalyst.com (press release) all 18 news articles » |
Media Advisory - Is the world of Multiple Sclerosis flat? - CNW Group (press release)
Posted Tue, 04/13/2010 - 07:04
CNW Group (press release) Understanding the relationship between chronic cerebrospinal venous insufficiency (CCSVI) and MS could open a whole new world for those with MS. ... |
Headlines: Raft race calls for sponsorship - TMD Celebrity News
Posted Tue, 04/13/2010 - 03:44
TMD Celebrity News Annual two-day race helps bikers stay in shape and raise funds for the National Multiple Sclerosis Society. Father-daughter duo, Steve & Allie, ... and more » |
Gilenia Reduces Relapse Rates In Multiple Sclerosis Therapy: Novartis - Pharmaceutical Business Review
Posted Tue, 04/13/2010 - 03:16
Pharmaceutical Business Review ... oral therapy for relapsing forms of multiple sclerosis (MS), reduced annual relapse rates (ARR) by 62% for treatment naive patients compared to placebo. ... Novartis investigational multiple sclerosis therapy Gilenia(R)* (FTY720) shown ...Trading Markets (press release) Novartis moves closer to first oral MS treatmentReuters New drug may prevent relapse in MS patientsNursing Times Nursing in Practice -The Press Association -Journal and Courier all 54 news articles » |
Large Body of Data on TYSABRI(R) to Be Presented at Annual Meeting of the ... - MarketWatch (press release)
Posted Tue, 04/13/2010 - 02:36
MarketWatch (press release) Multiple sclerosis is one of the most common neurological disorders, affecting more than 400000 people in the United States each year. ... Elan and Biogen present data on MS drugBusiness Financial News Wire Biogen Idec to present study data on TysabriZenopa all 20 news articles » |
Stem cell research forges ahead in Ecuador - Treatment Abroad
Posted Tue, 04/13/2010 - 01:57
Treatment Abroad Positive results have been noted in a variety of medical conditions utilizing stem cell therapies, including Parkinson's, multiple sclerosis, diabetes, ... and more » |
Novartis investigational multiple sclerosis therapy Gilenia®* (FTY720) shown ... - istockAnalyst.com (press release)
Posted Tue, 04/13/2010 - 01:49
istockAnalyst.com (press release) Oral Fingolimod (FTY720) vs Placebo in Relapsing-Remitting Multiple Sclerosis: 24-month Clinical Efficacy Results from a Randomized, Double-Blind, ... |
Novartis investigational multiple sclerosis therapy Gilenia(R)* (FTY720) shown ... - Trading Markets (press release)
Posted Tue, 04/13/2010 - 01:21
Trading Markets (press release) Oral Fingolimod (FTY720) vs Placebo in Relapsing-Remitting Multiple Sclerosis: 24-month Clinical Efficacy Results from a Randomized, Double-Blind, ... Novartis moves closer to first oral MS treatmentReuters all 13 news articles » |